FGF21 and Hepatic fibrosis: Moreover, treatment with LY2405319, an engineered FGF21 analogue, significantly decreases MASH scores, serum liver fibrosis markers, injury markers, and pro-inflammatory markers in mice with MASH (Lee et al., 2016).